The company invited supplier companies and external ESG specialists to discuss ESG-related requirements and recommendations as well as share successful cas...
Seegene Inc. (KQ096530), a leading South Korean company providing a total solution for PCR molecular diagnostics, announced on November 10 that it has rece...
Lunit SCOPE IO pivotal in first phase III trial successfully showing the efficacy of immunotherapy + chemotherapy for NSCLC patients with EGFR or ALK mut...
With a dedicated booth in the main exhibition hall, SK pharmteco solidifies its global position as the most trusted CDMO partner in the pharmaceu...
Phase 1 study for SB16, proposed biosimilar to Prolia, demonstrates pharmacokinetic (PK) bioequivalence between SB16, EU-sourced denosumab, and US-source...
.. First ovarian cancer therapy for ST oncology portfolio .. Phase 2 study demonstrated oregovomab in combination with chemotherapy improved progression f...
Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the su...
CBM brings extensive cell and gene therapy expertise to SK pharmteco portfolio and continues SK pharmteco’s strategy to deliver end-to-end, multi-mod...
Bristol Myers Squibb and Samsung Biologics have an existing manufacturing agreement for a commercial antibody cancer drug and have expanded the strategic r...
US-based startup Zenas BioPharma has entered into a license and collaboration agreement with Bristol Myers Squibb Company to develop and commercialise ob...
Neurophet, an artificial intelligence (AI) solution company for brain disease, announced its participation in the global startup innovation program 'Startu...
The HD-MAP platform technology offers user-friendly vaccines, allowing possible self-administration. Its room temperature stability revolutionizes distri...
Amarin Corporation plc (NASDAQ:AMRN) and Lotus Pharmaceuticals (1795:TT; “Lotus”) announced that the two companies have entered into a lo...
The study, consisting of single ascending-dose cohort and multiple ascending-dose cohort, has dosed the first of 36 planned study subjects. The Phase I cli...
© 2024 Biopharma Boardroom. All Rights Reserved.
